By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Yakult Honsha Co., Ltd. 

1-19 Higashi Shimbashi 1-chome
Tokyo      Japan
Phone: 03-3574-8960 Fax:



Company News
Debiopharm's Partner Yakult Honsha Announces Elplat Approbation In Gastric Cancer In Japan 11/24/2015 6:41:16 AM
AEterna Zentaris (AEZS): Partner Yakult Honsha Initiates Phase 1 Trial in Multiple Myeloma With Perifosine in Japan 6/28/2012 11:31:47 AM
AEterna Zentaris (AEZS) Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan 1/3/2012 9:28:16 AM
Proacta Inc. and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 8/3/2011 10:56:48 AM
AEterna Zentaris (AEZS) and Yakult Honsha Sign a Development, Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for the Japanese Market 3/9/2011 7:44:46 AM
Proacta Inc. and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proacta's PR509 Compound 2/22/2011 6:52:47 AM
Celsion Corporation (CLN) and Yakult Honsha Announce Treatment of First Patient in Japan in Celsion's Global Phase III ThermoDox(R) Trial for Primary Liver Cancer 10/27/2009 10:20:14 AM
Celsion Corporation (CLN) to Hold Conference Call to Discuss Its Announced Japan License Agreement for Thermodox(R) with Yakult Honsha 12/17/2008 9:46:38 AM
Celsion Corporation (CLN) Announces Exclusive Japan License Agreement with Yakult Honsha for ThermoDox(R); Agreement Includes $20.5 Million in License Fees 12/16/2008 2:09:19 AM
Yakult Honsha to Commence ThermoDox(R) Development Program in Japan 8/18/2008 8:51:16 AM